UroGen Pharma Ltd.
NASDAQ:URGN
13.1 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 82.713 | 64.357 | 48.042 | 11.799 | 0.018 | 1.128 | 8.158 | 17.53 | 0 | 0 | 0 |
| Cost of Revenue
| 9.361 | 7.654 | 5.157 | 1.009 | 0 | 1.803 | 0.6 | 0.028 | 0.113 | 0 | 0 |
| Gross Profit
| 73.352 | 56.703 | 42.885 | 10.79 | 0.018 | -0.675 | 7.558 | 17.502 | -0.113 | 0 | 0 |
| Gross Profit Ratio
| 0.887 | 0.881 | 0.893 | 0.914 | 1 | -0.598 | 0.926 | 0.998 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 45.614 | 52.906 | 47.642 | 47.31 | 49.297 | 36.934 | 18.697 | 10.287 | 10.515 | 4.008 | 2.334 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 60.199 | 39.571 | 8.811 | 6.417 | 1.895 | 0.89 | 1.055 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 93.274 | 82.838 | 87.535 | 90.219 | 60.199 | 39.571 | 8.811 | 6.417 | 1.895 | 0.89 | 1.055 |
| Other Expenses
| 0.838 | 0.072 | 0 | 0 | -0.284 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 138.888 | 135.744 | 135.177 | 137.529 | 109.496 | 76.505 | 27.508 | 16.704 | 12.41 | 4.356 | 3.389 |
| Operating Income
| -65.536 | -79.041 | -92.292 | -126.739 | -109.478 | -77.18 | -19.95 | 0.798 | -12.41 | -4.369 | -3.389 |
| Operating Income Ratio
| -0.792 | -1.228 | -1.921 | -10.742 | -6,082.111 | -68.422 | -2.445 | 0.046 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -32.788 | -28.987 | -17.079 | 1.629 | 4.332 | -0.1 | -0.031 | -2.739 | -0.279 | -0.107 | 0.083 |
| Income Before Tax
| -98.324 | -108.028 | -109.371 | -125.11 | -105.146 | -75.532 | -19.981 | -1.941 | -12.689 | -4.476 | -3.306 |
| Income Before Tax Ratio
| -1.189 | -1.679 | -2.277 | -10.603 | -5,841.444 | -66.961 | -2.449 | -0.111 | 0 | 0 | 0 |
| Income Tax Expense
| 3.92 | 1.135 | 1.449 | 3.374 | -4.616 | 0.125 | 0.019 | 0 | 0 | 0.081 | 0 |
| Net Income
| -102.244 | -109.163 | -110.82 | -128.484 | -100.53 | -75.657 | -20 | -1.941 | -12.689 | -4.557 | -3.306 |
| Net Income Ratio
| -1.236 | -1.696 | -2.307 | -10.889 | -5,585 | -67.072 | -2.452 | -0.111 | 0 | 0 | 0 |
| EPS
| -3.55 | -4.79 | -4.96 | -5.9 | -4.9 | -4.8 | -2.06 | -0.16 | -1.06 | -1.98 | -1.56 |
| EPS Diluted
| -3.55 | -4.79 | -4.96 | -5.9 | -4.9 | -4.8 | -2.06 | -0.16 | -1.06 | -1.98 | -1.56 |
| EBITDA
| -63.831 | -78.031 | -75.001 | -126.739 | -108.154 | -77.18 | -19.95 | 1.011 | -12.297 | -4.339 | -3.371 |
| EBITDA Ratio
| -0.772 | -1.212 | -1.561 | -10.742 | -6,008.556 | -68.422 | -2.445 | 0.058 | 0 | 0 | 0 |